Ims 2025 Myeloma Multiple. Berenson, md, describes ongoing efforts to evaluate treatment with jak inhibitors like ruxolitinib among patients with multiple myeloma. The future of managing precursor multiple myeloma lies in further refining how doctors can predict the likelihood of progression and developing interventions to prevent it.

The diagnosis requires ≥10% clonal bone marrow plasma cells or a. See the imf’s multiple myeloma events calendar for upcoming fundraisers, patient and family seminars, health care conferences, research summits and more.